Press releases
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
- Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
- Aurinia to Participate in Upcoming Investor Healthcare Conferences
- Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value
- Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.45 |
---|---|
High | 4.54 |
Low | 4.36 |
Bid | 4.49 |
Offer | 4.58 |
Previous close | 4.47 |
Average volume | 231.78 |
---|---|
Shares outstanding | 144.62m |
Free float | 133.85m |
P/E (TTM) | -- |
Market cap | 695.61m USD |
EPS (TTM) | -0.5454 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 11:32 BST.
More ▼